StonvexLoading…
StonvexStonvexStonvexCore line items from GMED's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.94B | $2.52B | $1.57B | $1.02B |
Operating Income | $479.82M | $165.99M | $133.14M | $227.95M |
Net Income | $537.87M | $102.98M | $122.87M | $190.17M |
EPS (Diluted) | $3.92 | $0.75 | $1.07 | $1.85 |
Total Assets | $5.30B | $5.25B | $5.09B | $2.08B |
Total Liabilities | $729.51M | $1.07B | $1.09B | $229.75M |
Cash & Equivalents | $526.16M | $784.44M | $467.29M | $150.47M |
Free Cash Flow OCF − CapEx | $588.77M | $405.21M | $165.22M | $104.42M |
Shares Outstanding | 137.06M | 137.86M | 114.63M | 102.64M |